Summary
This is a non-randomised, open-label trial with dose escalation of ERAS-601 monotherapy, followed by dose escalation of ERAS-601 in combination with other cancer therapies.
Once the monotherapy MTD and/or RD has been determined, then dose expansion of ERAS-601 monotherapy may commence with enrolment of study participants with advanced or metastatic solid tumours harbouring specific molecular alterations.
Once the combination therapy MTD and/or RD has been determined, then dose expansion of that combination may commence with enrolment of study participants with advanced or metastatic solid tumours harbouring specific molecular alterations.
ERAS-601 will be administered orally, and in the dose escalation phase will be administered in sequential ascending doses.
In the dose expansion phase, ERAS-601 will be administered at the recommended dose as determined from the dose escalation phase. For those enrolled in the ERAS-601 + cetuximab arm, cetuximab will be administered via intravenous infusion.
Please note, PCCTU are currently only recruiting participants with head and neck cancers at the moment.